<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols, Emma Hitt</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Eisenhauer, Elizabeth A.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Antiangiogenics in Ovarian Cancer: Where are We Now?</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">28-29</style></pages><abstract><style  face="normal" font="default" size="100%">Vascular Endothelial Growth Factor (VEGF) promotes ascites and effusions in ovarian cancer [Byrne AT et al. Clin Cancer Res 2003], and it is an independent adverse predictor of patient prognosis [Shen GH et al. Br J Cancer 2000]. Bevacizumab, a humanized monoclonal antibody that targets VEGF, has shown single-agent activity in Phase 2 epithelial ovarian cancer trials [Burger RA et al. N Engl J Med 2011]. This article provides an update on the data available from Phase 3 bevacizumab ovarian cancer trials.</style></abstract><number><style face="normal" font="default" size="100%">15</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>